Clostridium difficile colitis in patients after kidney and pancreas-kidney transplantation
Abstract: Limited data exist about Gostridium dijjicile colitis (CDC) in solid organ transplant patients. Bet ween 1/1/99 and 12/31/02.600 kidney and 102 pancreas-kidney allograft recipients were transplanted. Thirty·nine (5.5°,,) of these patients had CDC on the hasis of clinical and laboratory fmdings. Of these 39 patients, 35 have information available for review. CDC developed at a median of 30 days after transplantation, and the patients nndergoing pancreas-kidney transplantation had a slightly higher incidence of CDC than recipients of kidney alone (7.8% vs. 4.5%. P> 0.05). All but one patient presented with diarrhea. Twenty·four patients (64.9%) were diagnosed in the hospital. and CDC occurred during first hospitalization in 14 patients (40"'0). Treatment was with QI'al metronidazole (M) in 33 patients (94 %) and M + oral vancomycin (M + V) in 2 patients. Eight patients had recurrent CDC, which occurred at a median of 30 days (range 15-314) after the first episode. Two patients (5.7%) developed fulminant CDC, presented with toxic megacolon, and underwent colectomy. One of them died; the other patient survived after colectomy. CDC shou ld be considered as a diagnosis in transplant patients with history of diarrhea after antibiotic use. and should be treated aggressively before the infection becomes complicated.
Infections are the leading cause of morbidity and mortality in the early post-transplant period. More than 80% of recipients suffer at least one episode of infection in the first year (1. 2). The occurrence of infectious complications is closely related to immunosuppressive treatment. including induction, maintenance, and the treatment of acute rejection.
Although, many viral and bacterial opportunistic infections are well known in kidney and pancreas-kidney allograft recipients, Clostridium difficile colitis (CDC) is a less frequently described gastrointestinalmfec· tion in these patients. Clostridium difficile (CD) is one of the most common hospital-acquired (nosocomial) infections causing antibiotic-associated colitis (3) . CDC has been defined as the existence of diarrhea and CD toxin in the stool.
In this study, we identified our patients with CDC aiter kidney and pancreas-kidney transplantation and report the clinical presentation, timing of infection. risk factors, recurrence, and treatment.We also report twu pat ients with fulminant CDC (FCDC) after kidney transplantation. Data are expressed as mean ± SD and median with a range for highlY skewed distributions. Parametric and non-parametric tests including Student's t-test,WIlcoxon signed rank test and X 2 test were used as appro· priate. A probability value of P < 0.05 was considered as statistically sig nificant. Statistical analysis was done using SPSS for Wmdows version 11.0 (Chicago, IL, USA).
Material and methods

Between
Results
Among the 702 recipients, 39 (5.5%) patients were found to have CDC by laboratory and clinical findings. Thirty-five (mean age 53 ± 14 years. 26 male, 9 females) patients have data available for review. Twenty-seven of them were kidney and 8 patients were pancreas-kidney allograft recipi· ents ( Table 1 ). The etiology of renal failure was diabetes mellitus ill IS. for white blood cells, and only 2 (l3.3%) had white blood cells in the stool.
As a risk factor, 31 (88.6 %) patients had a history of antibiotIc use in pre vious 1 month. The main treatment was with oral metronidazole in 33 patients (94.3%) and with oral metronidazole and oral vancomyclll l!1 2 patients (5.7%). The patients who had preconditiuning had a slightl1 higher incidence of CDC than those not receiving preconditioning, but this difference was not statistically significant (7.3% vs. 4.2%, P> 0.05).
Eight patients (22.9%) had recurrent infection ( 
Clostridium difflCile colitis; NS, not significant. 
Table 2
Patients with recurrent CDC (N = patients, CDC has been reported to be more frequent in general surgery patients than in other hospitalized patients, with an association between CDC and prior CD diarrhea, prior antibiotic treatment, renal insufficiency, recent hospitalization, age of patient, and length of total hospital stay (5, 6). In their study, West et al. (7) found that CDC is not an uncommon infection in patients after kidney and pancreas-kidney transplantation and reported an incidence of 8%. Pediatric patients (16%) and pancreas-kidney recipients (15.5%) had a higher incidence of CDC than kidney alone (3.5%) recipients (7). In our patients, the overall incidence was 5.5°,;). The incidence tended to be higher in patients receiving antibody preconditioning than in those who did not; however this difference was not statistically significant. oped FCDC, a significantly higher incidence than for other hospitalized patients (1.6 %). Although immunosuppression seems to be a risk factor for development of FCDC, immunosuppressed patients had a better survival (58% vs. 37%) after development of FCDC than non·immunosup· pressed patients. In our study, we found that adult kidney and pancreas kidney recipients had a 5,5% incidence of CDC during 1999 2002, and it was significantly higher than the overall incidence in our hospital Kev"n et al: C. difficile colitis after transplantation
The treatment of FCDC is surgical, and total abdominal colectomy and ileostomy can be life saving; however, if the operation takes place after va so pressors are needed, the mortality rate increases significantly (7).
Therefore, early recognition of FCDC is very important. In their study, Altiparmak et a!. (10) colitis. This patient showed no response to metronidazole plus vancomy· cin, not even to the addition of cholestyramine and intravenous immuno· globulin, which can be effective for patients with multiple episodb of CDC (11, 12) . Eventually, this patient succumbed to inanition. [t IV,!, reo ported that asymptomatic carriers of CD have high serum antibody lev· els against toxin A, and patients with relapsing CDC have lower anti-tox· in antibody levels than patients with a single, brief episode of diarrhea (13) . Thus, it seems that an adequate immune response to CD appears to be an important mechanism for controlling infectious episodes and reo lapsing diarrhea.
Measures to prevent CDC include institution of contact isolation pre· cautions, and hand washing before and after patient contact. An important reduction has been noted in the incidence of CDC in our transplant patients receiving prophylaxis with metronidazole (1.1 % vs. 5.5 0/;" P = 0.009). This practice merits further study.
CDC is not an uncommon problem after kidney and kidney-pancreas 
